A serum-based DNA methylation assay provides accurate detection of glioma
Abstract
The detection of somatic mutations in cell-free DNA (cfDNA) from liquid biopsy has emerged as a noninvasive tool to monitor the follow-up of cancer patients. However, the significance of cfDNA clinical utility remains uncertain in patients with brain tumors, primarily because of the limited sensitivity cfDNA has to detect real tumor-specific somatic mutations. This unresolved challenge has prevented accurate follow-up of glioma patients with noninvasive approaches.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 09, 2021
- Source ID
- 10.1093/neuonc/noab023
Entities
People
- Abir Mukherjee
- Adam Robin
- Ana C. Decarvalho
- Ana Valeria Castro
- Antonio Iavarone
- Artem Sokolov
- Dhananjay A Chitale
- Houtan Noushmehr
- Ian Lee
- Jack Rock
- James Snyder
- Karam Asmaro
- Kevin Nelson
- Laila Poisson
- Maritza S Mosella
- Mark L Rosenblum
- Michael Wells
- Steven Kalkanis
- Tathiane M. Malta
- Thais S Sabedot
- Tobias Walbert
- Tom Mikkelsen
Organizations
- Columbia University
- Harvard Medical School
- Henry Ford Health
- National Institutes of Health
- United States Department of Defense